Another CD33-targeting antibody-drug-conjugate, AVE9633, anti-CD33 maytanisine, based on a humanized antibody clone My96, was tested pre-clinically and in phase I clinical trials in AML, and despite not achieving the desired therapeutic effect, had shown a remarkable lack of toxicity, even at saturating doses (>75 mg/kg), potentially making My96 binder a safer option for CAR T therapy (17, 18). Here, CD33 is linked to acute myeloid leukemia.